Spectrum Pharma (SPPI) Misses Q1 EPS by 1c

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 11/5/2026

1. HUBS
2. FIS
3. BROS
4. EXPE
5. ARM
6. QCOM
7. DDOG
8. CPAY
9. CHYM
10. W

Go back to Spectrum Pharma (SPPI) Misses Q1 EPS by 1c

Spectrum Pharmaceuticals Reports Continued Advancement of Robust, Late-Stage Pipeline and First Quarter 2015 Financial Results

May 7, 2015 4:00 PM EDT

Significant Progress in Q1 on Two Potential Blockbusters and Two Near-term NDAs SPI-2012, a novel long-acting GCSF: Positive Phase 2 data presented at Analyst Day, and final Phase 3 protocols have been sent to the FDA Poziotinib, a novel pan-HER inhibitor: Compelling Phase 1 data presented in breast cancer patients who had failed multiple other HER-2 directed therapies; multiple Phase 2 studies underway EVOMELA(CE-Melphalan), a propylene-glycol free Melphalan with improved stability; NDA review ongoing with positive FDA discussions; on track for approval decision on October 23, 2015... More